-
-
-
-
-
-
-
Immune Pharma (IMNP) Highlights New Clinical Data from Positive, Proof-of-Concept Phase 2a Trial of Bertilimumab in Bullous Pemphigoid
-
-
-
-
-
-
-
Immune Pharmaceuticals Issues Statement on Former Chief Executive Officer
-
-
-
-
-
-
-
Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018
-
-
-
-
-
-
-
Immune Pharma (IMNP) Receives Nasdaq Listing Determination
-
-
-
-
-
-
-
Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
-
-
-
-
-
-
-
Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018
-
-
-
-
-
-
-
Consolidated Research: 2018 Summary Expectations for Columbia Property Trust, Dr Pepper Snapple, Immune Pharmaceuticals, Air Products and Chemicals, Box, and ACADIA Pharma – Fundamental Analysis, Ke
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

